Lipegfilgrastim
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Lipegfilgrastim: Primary release disorder of platelets
One-Sentence Summary
Lipegfilgrastim is a pegylated G-CSF (granulocyte colony-stimulating factor) analogue, and its original indication is not recorded in the data compiled for this report. The TxGNN model predicts it may be effective for primary release disorder of platelets, but there are currently no clinical trials and no publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 0.9993 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this report. Lipegfilgrastim is a pegylated G-CSF analogue. It acts through the G-CSF receptor on the neutrophil lineage, and its established role is to stimulate neutrophil production.
Primary release disorder of platelets is a qualitative platelet function defect, not a problem of neutrophil numbers. No plausible mechanistic link between G-CSF receptor signalling and platelet secretion has been established. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not supported by clinical or literature data, so the prediction should be treated as a hypothesis, not a finding.
Other top-ranked predictions show the same pattern. All are Evidence Level L5 with no trials or publications. For several of them there are also mechanistic concerns. G-CSF mobilisation could worsen retinal neovascularisation, and G-CSF effects on bone turnover could cause bone loss, not benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10931H | Lonquex | Injection 6 mg in 0.6 mL single use pre-filled syringe | Not stated in the compiled data |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
No drug interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence, with no clinical trials, no publications and no plausible mechanistic link between G-CSF signalling and platelet secretion defects. The safety information needed for screening is also missing.
To proceed, the following is needed:
- The TGA-approved Product Information (PI), to confirm the original indication, warnings and contraindications
- Detailed mechanism of action data for lipegfilgrastim
- Preclinical or mechanistic evidence for a link between G-CSF receptor signalling and platelet release function
- A systematic literature search and trial registry search (including ANZCTR) for this indication
- Assessment of route compatibility and the risks specific to a platelet disorder population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.